CI

At a glance

ClinicalIndex Comparison Record
Phase 3Terminated· 74 enrolled
Drug / intervention
Apalutamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04409288
NCT04409288Phase 3Terminated
Terminated
CompareCT.gov

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.

Chinese University of Hong Kong·interventional·Posted Jun 1, 2020·Updated Jan 5, 2024

In Brief

A Phase 3 clinical trial evaluating Apalutamide and Enzalutamide for Prostate Cancer. Terminated early, enrolled 74 participants across 1 site.

Signals

Trial was terminated early

Detailed Summary

This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer. The primary objective is to investigate whether there is any difference in patient preference between apalutamide and enzalutamide in patients with recurrent or metastatic hormone-sensitive prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesHong Kong
CollaboratorsJanssen, LP

Timeline

Phase 3TerminatedFinished
202120222023202420252026
First PostedJun 1, 2020
Enrollment StartJul 20, 2020
Primary CompletionOct 16, 2023
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 6.1 years ago

Interventions

Apalutamidedrug

Androgen receptor inhibitor.

Enzalutamidedrug

Androgern receptor inhibitor